We are live on ! Find out more
NRIX icon

Nurix Therapeutics

138 hedge funds and large institutions have $721M invested in Nurix Therapeutics in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 39 increasing their positions, 44 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more call options, than puts

Call options by funds: $564K | Put options by funds: $335K

59% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 17

53% more capital inflows, than outflows

Capital inflows: $97.2M | Capital outflows: $63.6M

6% more funds holding

Funds holding: 130 → 138 (+8)

5.33% more ownership

Funds ownership: 95.01% → 100.34% (+5.3%)

11% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 44

Holders
138
Holders Change
+8
Holders Change %
+6.15%
% of All Funds
1.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
39
Reduced
44
Closed
17
Calls
$564​K
Puts
$335​K
Net Calls
+$229​K
Net Calls Change
-⁠$285​K

NRIX Hedge Fund Activity: Q1 2024 in Review

138 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q1 2024, worth a combined $721M — up 52% from $476M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new NRIX positions and 17 closed out — a net gain of 10 holders — while 39 added to existing stakes and 44 trimmed.

The largest buyer was State Street, adding an estimated $19.4M. The largest seller was Wasatch Advisors, cutting an estimated $16.3M.

  • 138 institutional investors held Nurix Therapeutics (NRIX) as of Q1 2024, up from 130 in Q4 2023.
  • Funds reported $721M of Nurix Therapeutics stock for Q1 2024, up 52% quarter-over-quarter.
  • 27 funds opened new Nurix Therapeutics positions in Q1 2024 and 17 closed out, a net change of +10 holders.
  • The largest Nurix Therapeutics buyer in Q1 2024 was State Street, an estimated $19.4M added.
  • The largest Nurix Therapeutics seller in Q1 2024 was Wasatch Advisors, an estimated $16.3M sold.

Based on aggregated 13F filings for Q1 2024.